Science & TechnologyPriority2026-02-01

Launch of Biopharma SHAKTI Scheme

Why focus: GS3 Sci-Tech: Flagship scheme launch with numeric targets. Tests biosimilars vs biologics concepts and 'How-Many-Correct' on budget outlays.

In News

What Happened

Finance Minister Nirmala Sitharaman announced the Biopharma SHAKTI scheme during the Union Budget 2026-27 on February 1, 2026. The scheme is backed by an outlay of Rs. 10,000 crore over five years. It seeks to build a complete domestic ecosystem for producing high-value biologics and biosimilars, establish a network of over 1,000 clinical trial sites, and promote alternatives to animal testing.

Why It Matters

This scheme is a critical pivot for India from manufacturing low-margin generic chemical drugs to developing complex, high-value biological medicines. By adopting advanced Non-Animal Methodologies (NAMs) like organoids, India aligns with global ethical standards and modern scientific practices, ensuring faster and more accurate drug discovery.

Background

History & Context

India has long been known as the 'pharmacy of the world', but this reputation was built primarily on low-margin generic chemical drugs. As global medicine shifts toward biologics (drugs produced from living organisms), India needed a focused strategy to capture this high-value market. Previous efforts like the National Biopharma Mission (Innovate in India, launched in 2017) laid the groundwork but lacked the massive funding required for an end-to-end ecosystem. Regulatory pathways were updated with the New Drugs and Clinical Trials Rules, 2019, yet traditional animal testing remained a major bottleneck. Globally, the US FDA's Modernization Act 2.0 (2022) paved the way for alternatives to animal testing. The Biopharma SHAKTI scheme consolidates these global regulatory shifts into a massive domestic financial push.

What Changed

▶
BEFORE: Funding for biologics research was fragmented and insufficient for large-scale scaling. NOW: A dedicated Rs. 10,000 crore outlay over five years specifically targets an end-to-end biologics and biosimilars ecosystem.
▶
BEFORE: Preclinical drug trials relied heavily on traditional in-vivo animal testing. NOW: The scheme prioritises a shift to Non-Animal Methodologies (NAMs) such as organoids and organ-on-a-chip technologies.
▶
BEFORE: Clinical trials faced delays due to a lack of standardised, ready-to-use testing sites. NOW: The scheme mandates the creation of a national network comprising over 1,000 accredited clinical trial sites.
▶
BEFORE: National Institutes of Pharmaceutical Education and Research (NIPERs) focused on broad pharmaceutical education. NOW: These institutes will play a specialised role in training a workforce for complex biologics manufacturing and NAMs.
▶
BEFORE: India captured only a small fraction of the global biosimilars market. NOW: Targeted ecosystem support aims to replicate India's generic drug success in the high-value biosimilars segment.

What Did NOT Change

The overarching regulatory authority remains with the Central Drugs Standard Control Organisation (CDSCO), and standard clinical trial phases (Phases I-IV) still apply. Furthermore, traditional animal testing is not completely banned; NAMs are prioritised and incentivised, but not made exclusively mandatory for all drug classes immediately.

Prelims Angle

NCERT Connection

This scheme strongly connects to Class 12 Biology Chapter 12 - Biotechnology and its Applications. The chapter explains how recombinant DNA technology is used to produce therapeutic drugs (like genetically engineered insulin) safely and efficiently in host organisms. Biopharma SHAKTI scales up this very concept, providing the industrial infrastructure to mass-produce complex recombinant therapeutics (biologics) and biosimilars. It also advances the chapter's discussion on using transgenic animals for vaccine safety testing by introducing modern NAMs (like organoids) as ethical and scientific alternatives.

Common Misconceptions

✗ Biosimilars are exactly identical to their reference biologic drugs, just like generic drugs are to chemical drugs.

✓ Unlike generic chemical drugs, biosimilars are highly similar but not perfectly identical to their reference biologics due to the natural variability of living biological systems used to produce them.

People conflate simple chemical synthesis (which produces exact molecular copies) with biological manufacturing (where host cells inevitably introduce slight, clinically insignificant variations).

✗ Non-Animal Methodologies (NAMs) mean that drugs are tested directly on humans after running computer simulations.

✓ NAMs heavily involve advanced in-vitro biological models like organ-on-a-chip and 3D organoids derived from human stem cells, which mimic human organ function without using living animals.

The term 'non-animal' leads people to think of purely digital (in-silico) models, ignoring the massive biological advancements in human tissue engineering.

Practice Questions

Q1

How Many Correct

Consider the following statements regarding the Biopharma SHAKTI scheme: 1. It aims to completely ban traditional animal testing for all preclinical trials in India by 2027. 2. The scheme supports the production of biosimilars, which are exact identical copies of reference biologics. 3. It proposes the establishment of a national network of over 1,000 accredited clinical trial sites. How many of the above statements are correct?

Q2

Match the Following

Match List I (Biopharma Terminology) with List II (Description): List I: A. Organoids B. Biosimilars C. Generic Drugs D. Organ-on-a-chip List II: 1. Microfluidic devices lined with living human cells to simulate organ level physiology 2. Exact chemical copies of small-molecule reference drugs 3. Highly similar clinical equivalents of complex biological drugs 4. 3D miniaturised and simplified versions of organs produced in vitro Select the correct answer:

Q3

Assertion & Reason

Assertion (A): The Biopharma SHAKTI scheme focuses on transitioning from traditional in-vivo animal testing to Non-Animal Methodologies (NAMs) like organoids. Reason (R): Animal models often fail to accurately predict human responses to complex biologics, leading to high failure rates in human clinical trials. Select the correct answer:

← Back to Day 10 overview